Medicines & supplements – Current GIS Alerts 2026
Found 735 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Levosimendan Kabi
Contamination with particles visible to the naked eye was found in the concentrate for solution for infusion, indicating a serious quality non-compliance of the product. Potential effects: thromboembolic and inflammatory complications, vascular damage, severe adverse effects after intravenous administration.
Egoropal
The product does not meet quality requirements due to a negative test result for the particle size analysis parameter, which is critical for the safety and efficacy of an injectable suspension. Potencjalne skutki: lack of treatment efficacy, adverse reactions, complications after injection.
Ozempic
Leaving on the market a medicinal product for which falsification has been confirmed poses a direct and real threat to health and potentially to patients’ lives; there is no confirmation of the composition of the falsified product or its effect on the body. Potential effects: poisoning, lack of treatment efficacy, severe complications.
Ozempic
Keeping a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially to life; there is no confirmation of the actual composition of the falsified product or its impact on pharmacological action. Potential effects: poisoning, lack of treatment efficacy, severe complications.
Clotidal MAX
It was found that the medicinal product does not meet its specified quality requirements due to a negative test result for the Appearance parameter. Potential effects: possible lack of treatment efficacy or complications resulting from the use of a product with improper quality.
Faringan
An incorrect benzocaine content, elevated level of an unknown impurity and total impurities, and inadequate tablet friability were found. Potential effects: lack of treatment efficacy, unpredictable adverse reactions, possible irritation or allergic reactions.
Trazodone Neuraxpharm
Stability test results showed that the hardness of some tablets was below the lower specification limit, which constitutes a real and direct threat to patients' health or life until the cause is clarified and any impact on the product’s efficacy and safety is excluded. Potential effects: lack of treatment efficacy, adverse reactions, complications.
Tadalafil Aurovitas
Tests by the National Medicines Institute showed that the product does not meet quality requirements due to a negative result for the parameter “release of tadalafil within 15 minutes”, which may mean improper release of the active substance from the tablet. Potential effects: lack of treatment efficacy.
Hycamtin
The identified deviation concerns the active substance content. Administration of the medicine with an increased amount of topotecan may negatively affect treatment tolerability; haematological toxic effects are dose-dependent and may pose a health risk to the patient. Potential effects: haematological toxicity, complications of oncological treatment.
Hycamtin
The identified deviation concerns the content parameter of the active substance topotecan; administering the medicine with an increased amount of topotecan compared to the declared dose may negatively affect treatment tolerance. Hematological toxic effects are dose‑dependent. Potential effects: hematological toxicity, complications of oncology treatment.
Benlek
The product does not meet the required quality specifications due to a negative result for the parameter “Chromatographic purity of thiamine hydrochloride”, indicating the presence of undesirable impurities. Potential effects: reduced treatment efficacy or unpredictable adverse reactions.
Tranexamic acid injection BP
A quality defect was found: the ampoule cannot be opened normally, it crumbles, and it is uncertain whether glass fragments have entered the inside and contaminated the solution, creating a risk of administering a medicinal product containing glass to the patient. Potential effects: poisoning, tissue damage, life-threatening complications.
Vendal retard
Due to morphine being released in a different amount than specified in the documentation, the impact on the course of therapy and the suspicion of a threat to the patient’s health or life cannot be excluded. Potential effects: overdose or insufficient analgesic effect, dependence, life-threatening complications.
Aciclovir Jelfa
Due to the detected presence of particles visible to the naked eye, a risk to the patient’s health or life cannot be excluded. Potential effects: complications after intravenous administration, vessel damage, embolism, severe systemic reactions.
Tresuvi
The presence of unidentified solid particles was found in the product, and the nature of the contamination and its cause have not been determined. Therefore, a risk to the patient’s health and life cannot be excluded. Potential effects: infusion complications, embolism, inflammatory reactions, life‑threatening events.
Gentamicin B.Braun
Cross-contamination of infusion solutions was identified in numerous batches of B. Braun products, meaning the presence of incorrect active substances or their residues in bottles intended for intravenous administration, breaching quality and safety requirements. Potential effects: severe adverse reactions, poisoning, lack of efficacy or complications of intravenous therapy.
Amikacin B.Braun
Cross-contamination of infusion solutions was detected in the specified batches of medicinal products. Potential effects: poisoning, adverse reactions, infectious complications or lack of treatment efficacy.
Amikacin B.Braun
Cross-contamination of infusion solutions was found in many batches of B. Braun medicinal products, which may mean the presence of an incorrect active substance or its traces in intravenously administered preparations. Potential effects: poisoning, severe adverse reactions, lack of treatment efficacy.
Amikacin B.Braun
Cross-contamination of infusion solutions in the listed medicinal product batches was detected, which may mean the presence of incorrect substances in the medicine. Potential effects: poisoning, lack of treatment efficacy, serious complications.
Gentamicin B.Braun
Cross-contamination of infusion solutions in the specified batches of B. Braun medicinal products was detected and reported in the Rapid Alert system by the Hessian State Office for Health and Care. Potential effects: risk of incorrect dosing, toxicity, lack of therapeutic efficacy or serious complications after intravenous administration.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.